Nuclear Cardiology: Overview
Myocardial perfusion, function, viability, and infiltrative disease imaging
Quick Answer
Nuclear cardiology uses radiotracers to assess the heart's perfusion (myocardial perfusion imaging, MPI, by SPECT or PET), function (gated ejection fraction and volumes; MUGA), viability (FDG-PET perfusion–metabolism mismatch), and infiltrative disease (Tc-99m-PYP for transthyretin amyloid; FDG for sarcoidosis). Its central role is detecting and risk-stratifying coronary artery disease, but its scope now spans amyloid, sarcoid, and absolute myocardial blood-flow quantification.
Scope & Definition
Nuclear cardiology is the application of radiotracer imaging to the heart. The historically dominant question is ischemia and infarct (MPI), but the field now owns two booming infiltrative-disease areas (ATTR amyloid by bone-tracer imaging, sarcoid by suppressed-FDG imaging), quantitative flow by PET, and function by gated imaging and MUGA.
What Nuclear Cardiology Answers
- Is there ischemia, and how much? Reversible perfusion defects on stress imaging (extent/severity by summed scores).
- Is there prior infarct / scar? Fixed defects at rest and stress.
- Is dysfunctional myocardium viable? FDG perfusion–metabolism mismatch (hibernating myocardium).
- What is the ejection fraction and are there high-risk features? Gated LVEF/volumes, transient ischemic dilation (TID).
- Is there infiltrative cardiomyopathy? PYP for ATTR amyloid; FDG for cardiac sarcoidosis.
- Absolute coronary flow? PET-derived MBF and flow reserve (balanced multivessel disease, microvascular dysfunction).
Clinical Indications (Appropriate Use)
MPI is used for symptomatic patients with intermediate pretest probability of CAD, risk stratification of known CAD, preoperative assessment in selected higher-risk surgery, and evaluation after revascularization or with new/worsening symptoms. Appropriate-use criteria discourage routine testing in asymptomatic low-risk patients. Infiltrative-disease imaging (PYP, FDG-sarcoid) is indication-specific.
Modalities at a Glance
| SPECT | PET | |
|---|---|---|
| Perfusion tracers | Tc-99m-sestamibi/tetrofosmin, Tl-201 | Rb-82, N-13-ammonia, F-18-flurpiridaz (Flyrcado) |
| Absolute flow (MBF/MFR) | Limited | Routine |
| Attenuation correction | CT or prone imaging | Inherent (CT) |
| Image quality (large patients) | Lower | Higher |
| Stress type | Exercise or pharmacologic | Usually pharmacologic (short half-lives) |
| Radiation | Higher (esp. Tl-201) | Generally lower (short-lived tracers) |
The Three-Layer Read
Every MPI study is read as three layers, not one:
- Perfusion — extent/severity of ischemia and scar (SSS/SRS/SDS, % myocardium).
- Cavity — transient ischemic dilation (TID).
- Function — gated LVEF, volumes, wall motion, and (thallium) lung uptake.
High-risk features cluster: a large ischemic burden with TID and post-stress LV dysfunction is a very different patient from an isolated small defect.
SPECT vs PET vs Newer Questions
SPECT MPI remains the high-volume workhorse. PET adds inherent CT attenuation correction, higher image quality (valuable in larger patients), lower radiation, and absolute MBF/MFR for balanced disease and microvascular dysfunction. Beyond ischemia, nuclear cardiology now owns ATTR amyloid (bone-tracer PYP with a monoclonal-screen gate) and cardiac sarcoid (suppression-prepped FDG).
The Prognostic Frame (and ISCHEMIA)
A normal stress MPI carries a low annual hard-event rate (the "warranty period"), and event risk scales with ischemic burden. But the ISCHEMIA trial reframed how that burden should drive management: in stable CAD, moderate-to-severe ischemia alone did not identify a survival benefit from a routine invasive strategy over optimal medical therapy. Nuclear cardiology's role is risk stratification and guiding whether/what to test or treat next — integrated with symptoms and clinical context, not an automatic trigger to catheterize.
Differential / Problem Areas
- Attenuation artifact (breast/diaphragm) vs true scar — resolved by attenuation correction and gated wall motion.
- Balanced multivessel ischemia normalizing relative perfusion — unmasked by PET MFR, TID, and post-stress dysfunction.
- Infiltrative cardiomyopathy (amyloid/sarcoid) presenting as unexplained wall thickening/heart failure.
Reporting Checklist
- Integrate perfusion + cavity + function into one risk statement, naming coronary territories.
- Report extent and severity (summed scores / % ischemic), not just "abnormal."
- State stress adequacy, attenuation-correction method, and image-quality caveats.
- For infiltrative studies, follow the PYP (monoclonal-screen + SPECT) and sarcoid (dietary-prep) disciplines.
Board Pearls
Read every study as three layers — perfusion (SSS/SRS/SDS, % myocardium), cavity (TID), and function (gated LVEF, wall motion) — because high-risk features cluster; perfusion extent and severity, not just presence, drive prognosis.
PET enables absolute flow: a globally reduced flow reserve (MFR) can unmask balanced multivessel ischemia and microvascular dysfunction that relative perfusion normalizes away — plus inherent attenuation correction and better images in larger patients.
ISCHEMIA reframed the prognostic-to-management link: in stable CAD, ischemia severity alone did not show a survival benefit from routine invasive management over optimal medical therapy — so nuclear cardiology risk-stratifies and guides, integrated with symptoms, rather than automatically mandating revascularization. Beyond ischemia, the field now also owns ATTR amyloid (PYP) and cardiac sarcoid (FDG).
Related Pages
- Protocols: MPI SPECT, cardiac PET perfusion, MPI interpretation & grading, stress testing, myocardial viability, MUGA, cardiac reporting.
- Infiltrative disease: cardiac amyloidosis and cardiac sarcoidosis.
Figure / Diagram Suggestions
- A three-layer read schematic (perfusion / cavity / function → integrated risk).
- A SPECT vs PET capability matrix.
- A nuclear-cardiology scope map (ischemia, viability, amyloid, sarcoid, flow).
Common Pitfalls
- LBBB or ventricular-paced rhythm produces a reversible septal defect unrelated to LAD disease — use vasodilator (not exercise) stress to reduce this artifact.
- Caffeine, methylxanthines, or theophylline/aminophylline within ~12 hours blunt adenosine/regadenoson hyperemia, causing a false-negative vasodilator study.
- Submaximal exercise (failure to reach target heart rate, without adjunctive vasodilator) undercalls ischemia — report stress adequacy.
- Subdiaphragmatic bowel/liver activity adjacent to the inferior wall can create or mask inferior defects; patient motion produces artifactual defects.
- Arrhythmia or frequent ectopy degrades gating and can spuriously lower the calculated LVEF.
Self-Check (Board-Style)
Q1. A relative SPECT perfusion scan looks uniform, but the patient has severe three-vessel disease at angiography. How could PET have helped?
Answer: Balanced multivessel ischemia can normalize relative perfusion; PET-derived absolute MBF/flow reserve (MFR) shows a globally reduced reserve, unmasking the disease (as do TID and post-stress dysfunction).
Q2. How did the ISCHEMIA trial change interpretation of a large ischemic burden in stable CAD?
Answer: Ischemia severity alone did not identify a survival benefit from a routine invasive strategy over optimal medical therapy — nuclear cardiology risk-stratifies and guides rather than automatically mandating catheterization.
Q3. Which three layers should every MPI report integrate?
Answer: Perfusion (extent/severity of ischemia and scar), cavity (transient ischemic dilation), and function (gated LVEF, volumes, wall motion) — combined into a single risk statement.
Q4. Beyond coronary disease, name the two infiltrative cardiomyopathies nuclear cardiology now diagnoses and their tracers.
Answer: ATTR cardiac amyloidosis (bone-tracer Tc-99m-PYP, with a monoclonal screen) and cardiac sarcoidosis (suppression-prepped FDG).
Evidence & sources
https://nuc.med/nuclear-cardiology-overview/ Report an issue